EVLiXiR is an innovative biotechnology company focusing on providing researchers with comprehensive solutions in the life science of exosome. Based on in-depth research and unique insights into exosomes, we have successfully developed the mass spectrometry-based exosome biomarker discovery diagnostic technology platform and the scaffold-based targeted delivery of active molecules therapeutic technology platform. At present, the company has a R&D team with more than 20 people, and has provided high-quality products of exosome and professional technical services for a number of Grade A tertiary hospitals and pharmaceutical companies. Since its establishment, we have always insisted on the business ethics of "Focusing on the needs of customers", and we have constantly updated and iterated our technology. We have published a number of advanced results in PNAS, Nature Protocols, ACS APPL MATER INTER, Molecular cancer, and many other prestigious journals. In addition to providing diagnostic and therapeutic related technical services, we have also developed a series of products related to exosome and proteomics research to promote the development of the industry of exosome.